Coloplast A/S Non-GAAP EPS of DKK 3.86, revenue of DKK 6.96B; reaffirms FY outlook

* Coloplast A/S press release [https://tools.euroland.com/tools/PressReleases/GetPressRelease/?ID=7779900&lang=en-GB&companycode=services] (OTCPK:CLPBF [https://seekingalpha.com/symbol/CLPBF]): Q3 Non-GAAP EPS of DKK 3.86.
* Revenue of DKK 6.96B (+1.2% Y/Y).
* Organic growth rates by business area: Ostomy Care 6%, Continence Care 8%, Voice and Respiratory Care 9%, Advanced Wound Care 4% and Interventional Urology 4%.
* EBIT1 was DKK 1,915 million, a 2% increase from last year. The EBIT margin1,2 was 28%, against 27% last year.
* FY 2024/25 GUIDANCE IS UNCHANGED, with organic growth of around 7% and an EBIT margin before special items of 27-28%. • Organic growth now includes the negative impact from the product return in Advanced Wound Dressings in China, partly offset by good momentum in the other business areas. Reported growth in DKK is now expected to be 3-4%, with around 2%-points negative impact from currencies and around 1.5%-points negative impact from the Skin Care divestment. • The assumptions on the reported EBIT margin before special items are largely unchanged. • Special items expectations are unchanged, around DKK 450 million. • Expectations on capital expenditures and tax rate (ordinary and effective) are also unchanged.

MORE ON COLOPLAST A/S

* Coloplast: Despite The Drawdown, Still Not A Buy [https://seekingalpha.com/article/4813417-coloplast-despite-the-drawdown-still-not-a-buy]
* Coloplast: Finally Getting Buyable [https://seekingalpha.com/article/4794878-coloplast-finally-getting-buyable]
* Seeking Alpha’s Quant Rating on Coloplast A/S [https://seekingalpha.com/symbol/CLPBY/ratings/quant-ratings]
* Historical earnings data for Coloplast A/S [https://seekingalpha.com/symbol/CLPBY/earnings]
* Dividend scorecard for Coloplast A/S [https://seekingalpha.com/symbol/CLPBY/dividends/scorecard]